Pure Global
NCT06207058

Evaluation of a Screen and Treat Protocol for Influenza

Evaluation of a Screen and Treat Protocol for Influenza in Socially Vulnerable Communities.
Tricore, Inc·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Influenza
Drug/Device/Intervention
Baloxavir Marboxil
Study type
Observational
Intervention type
drug
Sponsor & location
Primary sponsor
Tricore, Inc
Timeline & enrollment
Phase
N/A
Start date
Jan 15, 2024
End date
Jul 01, 2024
Enrollment
600 participants
Primary outcome

Mitigation of Influenza Transmission

Summary

This study seeks to demonstrate that the laboratory can mitigate respiratory virus
 transmission in underserved populations by using laboratory data to identify communities at
 risk for increase vial activity (hot spots) and intervening with a test-to-treat model
 provides increased access to influenza diagnostics and treatment in vulnerable and
 underserved communities.

ICD-10 classifications
Influenza and pneumoniaInfluenza due to identified seasonal influenza virusInfluenza with other manifestations, seasonal influenza virus identifiedInfluenza with pneumonia, seasonal influenza virus identifiedInfluenza due to identified zoonotic or pandemic influenza virus
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06207058
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06207058 through Pure Global AI's free database. This phase not specified trial is sponsored by Tricore, Inc and is currently Not yet recruiting. The study focuses on Influenza. Target enrollment is 600 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.